PDS Biotechnology Co. (NASDAQ:PDSB) Short Interest Down 18.6% in July

PDS Biotechnology Co. (NASDAQ:PDSB) was the recipient of a large decline in short interest in July. As of July 15th, there was short interest totalling 5,700,000 shares, a decline of 18.6% from the June 30th total of 7,000,000 shares. Based on an average daily volume of 626,300 shares, the short-interest ratio is presently 9.1 days.

PDS Biotechnology Stock Down 9.4 %

Shares of PDS Biotechnology stock traded down $0.36 on Tuesday, reaching $3.46. The company’s stock had a trading volume of 496,511 shares, compared to its average volume of 751,362. PDS Biotechnology has a 52 week low of $2.53 and a 52 week high of $6.85. The firm’s fifty day simple moving average is $3.25 and its two-hundred day simple moving average is $4.03. The company has a market capitalization of $126.91 million, a price-to-earnings ratio of -2.59 and a beta of 1.92. The company has a quick ratio of 4.56, a current ratio of 4.56 and a debt-to-equity ratio of 0.45.

PDS Biotechnology (NASDAQ:PDSB) last posted its earnings results on Wednesday, May 15th. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.07. Equities analysts anticipate that PDS Biotechnology will post -1.46 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Kathleen S. Wright Associates Inc. bought a new position in PDS Biotechnology in the 1st quarter worth $28,000. Tower Research Capital LLC TRC increased its holdings in PDS Biotechnology by 530.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 9,046 shares of the company’s stock worth $45,000 after acquiring an additional 7,612 shares in the last quarter. SG Americas Securities LLC bought a new stake in PDS Biotechnology during the 4th quarter worth approximately $52,000. Tempus Wealth Planning LLC purchased a new position in PDS Biotechnology during the second quarter valued at approximately $55,000. Finally, Inspirion Wealth Advisors LLC boosted its position in shares of PDS Biotechnology by 1.4% in the second quarter. Inspirion Wealth Advisors LLC now owns 359,894 shares of the company’s stock worth $1,054,000 after purchasing an additional 4,917 shares during the period. Institutional investors own 26.84% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on PDSB shares. HC Wainwright restated a “buy” rating and set a $21.00 target price on shares of PDS Biotechnology in a report on Wednesday, June 12th. B. Riley reduced their price objective on PDS Biotechnology from $11.00 to $9.00 and set a “buy” rating for the company in a research report on Wednesday, June 12th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of PDS Biotechnology in a report on Thursday, May 9th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $16.67.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.